- Home
- Editorial
- News
- Practice Guidelines
- Anesthesiology Guidelines
- Cancer Guidelines
- Cardiac Sciences Guidelines
- Critical Care Guidelines
- Dentistry Guidelines
- Dermatology Guidelines
- Diabetes and Endo Guidelines
- Diagnostics Guidelines
- ENT Guidelines
- Featured Practice Guidelines
- Gastroenterology Guidelines
- Geriatrics Guidelines
- Medicine Guidelines
- Nephrology Guidelines
- Neurosciences Guidelines
- Obs and Gynae Guidelines
- Ophthalmology Guidelines
- Orthopaedics Guidelines
- Paediatrics Guidelines
- Psychiatry Guidelines
- Pulmonology Guidelines
- Radiology Guidelines
- Surgery Guidelines
- Urology Guidelines
Compound in green tea could help combat tuberculosis
A compound present in the green tea plant may be beneficial for combating tuberculosis (TB).
Singapore: An antioxidant called epigallocatechin gallate (EGCG) present in the green tea plant can inhibit the growth of a bacteria strain that causes tuberculosis, according to a recent study. This would pave the way for potential novel drugs to be developed for the infectious disease.
Tuberculosis (TB), caused by the bacteria Mycobacterium tuberculosis (Mtb), is one of the most important infectious diseases worldwide. One-third of the world population is latently infected by Mtb. During infection Mtb undergoes a wide range of metabolic changes, which correlate with either replicative growth or non-replicative persistence.
The EGCG binds to an enzyme providing biological energy for cellular activity. The process results in dip in the amount of energy the bacteria has for carrying out the cellular processes vital for growth and stability, such as cell wall formation.
Thomas Dick, National University of Singapore, Singapore, and colleagues also identified the exact sites on the enzyme at which the EGCG needs to bind to in order to affect energy production in the bacterial cell. A patent has been filed for the identification of the EGCG as a possible form of treatment for tuberculosis.
While there are already drugs that target mycobacterium tuberculosis (M. tuberculosis) - the bacteria that causes the airborne disease - new ones are needed because the bacteria is increasingly showing resistance to many of the drugs.
Read Also: Antioxidant in green tea may have answer to threat of antibiotic resistance
Professor Gerhard Grüber from the NTU School of Biological Sciences said: "Though tuberculosis is curable, the success of current drugs on the market is increasingly being overshadowed by the bacteria's clinical resistance. Our discovery of the EGCG's ability to inhibit the growth of M. tuberculosis will allow us to look at how we can improve the potency of this compound in green tea, and other similar compounds, to develop new drugs to tackle this airborne disease."
How EGCG disrupts tuberculosis
Cells require energy for vital processes such as cell wall formation to take place. They get their energy from an energy storage molecule made by an enzyme called ATP synthase. Without energy for essential cellular activity, a cell loses its stability and eventually dies.
To determine the factors affecting the production of ATP synthase, and thus the amount of energy a bacterial cell has for growth, the NTU-led team studied Mycobacterium Smegmatis and Mycobacterium Bovis, both of which belong to the same family as M. tuberculosis. These mycobacterial strains share a similar structural composition.
The team first found that alterations to the genetic code for ATP synthase resulted in an enzyme that produced fewer energy storage molecules in the bacterial cells, slower cell growth, and an altered colony shape.
With this data, the scientists then screened for and found 20 compounds that could possibly bind to ATP synthase and cause the same blocking effect, and then tested them for their efficacy. Only EGCG, a natural antioxidant that occurs in a large amount in green tea, showed it had the same crucial effect of reducing energy storage molecules in the bacterial cell.
The NTU-led team is now looking at optimizing the activity of EGCG for increased efficiency and potency in fighting the tuberculosis bacteria. Their ultimate goal is to develop a drug cocktail that will tackle multi-drug resistant tuberculosis.
Read Also: FDA approves medication for highly drug resistant Tuberculosis
The study, "Disrupting coupling within mycobacterial F-ATP synthases subunit ε causes dysregulated energy production and cell wall biosynthesis," is published in the journal Scientific Reports.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd